Local, national & international business news and events.
NEW YORK & MORRISTOWN, N.J.–(BUSINESS WIRE)–Accenture (NYSE: ACN) has helped the U.S. subsidiary of Swedish pharmaceutical company Orexo launch its first digital therapeutic, vorvida®, for patients in the United States dealing with problematic alcohol use. vorvida® is a web-based digital platform that
OLDWICK, N.J.–(BUSINESS WIRE)–AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of “a” of First American Title Insurance Company (Omaha, NE) and its title subsidiaries, which are referred to as First
TINTON FALLS, N.J.–(BUSINESS WIRE)–#acquisitions–World Insurance Associates LLC (WIA), a Top 100 Insurance Agency, announced today that it acquired Fairways Insurance, Inc. (“Fairways”) of Cinnaminson, NJ on November 1, 2020. Terms of the transaction were not disclosed. Fairways is a full-service insurance agency
Bet Section Delivers Suite of New Personalized Betting Features, Further Deepening theScore’s Industry-Leading Media and Gaming Integrations TORONTO–(BUSINESS WIRE)–$SCR #sportsbetting—Score Media and Gaming Inc. (TSX: SCR) (“theScore” or the “Company”) today debuted Bet Section, its most integrated and personalized suite of betting
• Metagenomi is a genomic medicines company pioneering precision gene editing systems to advance curative therapies for oncology and genetic diseases • Proprietary and wholly owned gene editing platform offers the potential to expand the range of treatable diseases and to improve patient
Results for our CD19-targeted CAR T cell therapy lisocabtagene maraleucel (liso-cel) in patients with heavily pretreated mantle cell lymphoma and relapsed/refractory chronic lymphocytic leukemia Data showcasing BCMA-targeted CAR T cell therapy idecabtagene vicleucel (ide-cel), including updated results from the Phase 1 CRB-401
The U.S. 150-day delinquency rate reached its highest level since at least January 1999 Forbearance provisions have helped foreclosure rates maintain historic lows IRVINE, Calif.–(BUSINESS WIRE)–#Foreclosure–CoreLogic® (NYSE: CLGX), a leading global property information, analytics and data-enabled solutions provider, today released its monthly
LENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus Sunitinib Results of Investigational Phase 3 KEYNOTE-581/CLEAR Trial (Study 307) to be Presented at Upcoming Medical Meeting KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK): KEYTRUDA®
Deucravacitinib, the first and only novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor in clinical studies across multiple immune-mediated diseases, showed significantly greater ACR 20 responses compared to placebo at 16 weeks and met all key secondary endpoints Deucravacitinib was well-tolerated with